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Abstract
A significant progress has been made in describing cellular hierarchy and the stem cell 
niche in the human mammary gland. Mammary stem and progenitor cells exist in two 
different states: epithelial-like and mesenchymal-like. Several features of the mammary 
stem cells predispose them to play a critical role in breast cancer initiation, progression 
and metastasis. Signaling pathways contributing to the self-renewal, such as Wnt, Notch, 
Hh and BMP, have been shown to be linked with breast cancer stem cells. Furthermore, 
biomarkers connected with stemness, such as CD44, CD24, EpCAM and ALDH1, have 
been identified and used to characterize these cells. Additionally, many different miRNA 
families and microenvironmental factors were shown to regulate a lot of cancer stem cells 
properties and maintain their stemness. All these findings have started a new era of breast 
cancer research. In present breast cancer, stem cells have become the targets of breast 
cancer therapy, although the tests are mainly on the basic stage level. Since the cancer 
stem cells are able to escape chemotherapy and are resistant to drugs, radiotherapy and 
apoptotic processes, the therapeutic targeting is mostly concentrated on the disruption 
of survival signaling pathways and the use of modern technology, like nanotechnology.
Keywords: cancer stem cells, breast cancer, MaSC, BCSCs, stem cell niche, 
miRNA, EMT
1. Introduction
As most epithelia, mammary epithelium continuously replaces dead or damaged cells during 
the whole life of an animal and this process called tissue homeostasis is critical for adult tis-
sues maintenance. Typically, epithelial tissue homeostasis is maintained through the presence 
of stem cells (SC). They are functionally defined in connection with their ability to self-renew 
and differentiate into cell lineages of their original tissue [1–3]. Mammary stem cells (MaSC) 
are capable of generating the complex bilayer system of the mammary epithelium composed 
of basal (myoepithelial) and luminal (secretory) epithelial cells. In addition, there are mesen-
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chymal stem cells (MSCs), representing the stromal (fat pad) part of this organ [1]. According 
to current knowledge, scientists had made the model of SC mitotic division, which can be 
symmetric or asymmetric. During symmetric division, stem cell gives two daughter stem cells 
and it allows for the expansion of stem cell population. When a stem cell undergoes asym-
metric division, one stem cell is obtained maintaining the self-renewal properties, whereas 
the another cell is called a progenitor cell. Progenitor cells have a more restricted potential 
in terms of their renewal and differentiation. Progenitor cells also have limited proliferation 
capacity and can undergo senescence [1, 2].
Several features of MaSC make them plausible sites for breast cancer (BC) initiation. Breast 
cancer is a potentially life-threatening malignant tumor that still causes high mortality among 
women. Decreasing mortality rates has been achieved, that is, by efficient screening strate-
gies [4]. Still, BC is ranked on the second place among cancer types regarding mortality [5]. It 
has been estimated that approximately 1.3 million females develop BC each year with around 
465,000 expected to succumb to the disease [6–8]. MaSC have been postulated to underlie the cel-
lular heterogeneity observed in human breast cancers due to their preserved replicative capacity 
and differentiation potential, resulting in prolonged life span and thus increased probability of 
harboring and accumulation of mutations [9, 10]. The cancer stem cell (CSC) fraction typically 
constitutes 1–5% of the tumor size [8, 11]. In the healthy human mammary gland, SC account for 
approximately 8% of the cells [12]. The concept of CSC has led to the development of new theo-
retical models explaining the cellular origin of cancer [13, 14]. One theory, called the stochastic 
theory, claims that every single cell can potentially become cancerous in the appropriate micro-
environment. However, differentiated cells are probably unable to accumulate a sufficient num-
ber of mutations in order to become neoplastic because of their shorter life span. Second theory, 
called the hierarchy (CSC) theory, suggests that CSC are more likely to initiate the tumor, as 
they have longer life span, increased migratory and proliferative potential and advanced DNA 
repair mechanisms. Since it is more probable that these two models coexist, a dynamic version 
of the CSC model has been developed, suggesting that within the tumor hierarchy, differenti-
ated tumor cells may undergo dedifferentiation as a result of microenvironmental influences. In 
addition to the generation of cells with stem-like properties, the tumor microenvironment is also 
involved in the preservation of the established CSC subpopulation [15, 16].
Increasing evidence demonstrates that CSC play a critical role not only in BC initiation, but 
also in progression and metastasis [13]. Accumulating evidence indicates that the local recur-
rent and/or distant metastatic tumors, which constitute the major causes of lethality in the 
clinic, are related to the aggressive phenotype of a small fraction of cancer stem cells, tumor-
initiating cells (TICs) or cancer metastasis-initiating cells (CMICs) [17].
Breast cancer stem cells (BCSCs) are able to escape chemotherapy due to elevated expression 
of ABC transporters that enable them to efflux some chemotherapeutic drugs [13]. They are 
resistant to apoptosis (they also express high levels of anti-apoptotic proteins, such as sur-
vivin and Bcl-2) and show drug resistance [11]. In addition, the activity of BCSCs can enhance 
and the ratio of side population can increase after radiation treatment. Furthermore, BC has 
capability to resist radiotherapy [17–19]. Therefore, it has been suggested that BCSCs might 
be responsible for tumor regrowth and the development of drug resistance [2, 13, 17].
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Identification of BCSCs represents a major step forward in elucidation of the BC tumor hier-
archy and has started a new era of breast cancer research. Still, in present, there is no uniform 
approach, which would allow for a quick and simple detection of BCSCs in solid tumors. 
Therefore, a lot of scientific studies are focused on targeting BCSCs in BC therapy in different 
ways, using the current knowledge about those cells. For example, BCSCs are characterized 
by the activation of stemness-related pathways, such as the Notch and Wnt pathways and by 
the expression of certain stem cell markers. Since CSC are highly resistant to chemotherapy, 
additional treatment of BC patients with BCSC-specific drugs and inhibitors, which target the 
Wnt or Notch pathway, respectively, will be required [2].
2. The concept of stem cell hierarchy in the mammary gland
The mammary epithelial tissue forms a highly organized branched bilayered ductal network 
consisting of basal myoepithelial cells and luminal (secretory) epithelial cells [1, 20]. Distinct 
markers characterize luminal and basal cells. Luminal cells express cytokeratins (CKs) 8/18 
and 19, as well as other molecular markers, such as MUC1, GATA3 and CD24. Basal myoepi-
thelial cells express CK14 (50 kDa), CK5 (58 kDa) and CK17 (46 kDa), as well as smooth muscle 
actin (SMA) and vimentin [21]. Numerous scientific reports have provided evidence of exis-
tence of a much more complex mammary epithelial hierarchy, which is responsible for tissue 
growth and maintenance during periods of development and homeostasis [20]. Mammary 
cell proliferation, turnover and tissue regeneration are functions of MaSC [21, 22]. To present 
the idea in a simplified model, progenitor cell lineages are derived strictly from bi-potent or 
multi-potent stem cells. Then, they divide and differentiate into the epithelium of adult mam-
mary gland composed of both matured luminal and basal cells [23] (Figure 1A). The scientists 
have identified different subpopulations of cells in human and mouse mammary gland, using 
cell sorting techniques [20]. Subsets of mammary epithelial cells (MEC) were characterized 
using different surface markers. Accordingly, CD24 and EpCAM are known to be the luminal 
cell markers and CD49f and CD29 are the basal cell markers. This diversification is invariably 
used in classifying of luminal and basal MEC populations.
The perspective of MaSC isolation, which then were be able to give rise to an entire mammary 
epithelial tree upon transplantation of a single stem cell [24, 25] and the phenotypic identifica-
tion of several mammary epithelial progenitor cell (MaPC) populations [26, 27], has enhanced 
our current understanding of the differentiation hierarchy [28]. Furthermore, in vivo genetic 
tracing experiments have shown that both cell types contribute to morphogenesis in puberty 
and pregnancy and ductal maintenance in the adult gland [28].
To characterize MaSC, a clear distinction between normal stem cells and tumor stem cells 
must be made. Emerging evidence suggests that normal breast cells, as well as breast cancer 
stem and progenitor cells, exist in two different states, epithelial-like and mesenchymal-like 
[27, 29, 30] (Figure 1B). Recent studies revealed that in the case of human BCSCs, epithelial-
like stem cells express aldehyde dehydrogenase (ALDH+), whereas mesenchymal-like stem 
cells are characterized by CD44⁺/CD24⁻ surface expression [29, 31–33].
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Figure 1. The simplistic draft of hierarchical model of human mammary gland stem cells (A) and correlation of stem 
cells with breast cancer (BC) subtypes (B). Bi-potent or multi-potent stem cells (with self-renewal ability) give rise to 
lineage-restricted bi-potent progenitor cells. These progenitors then divide and differentiate into the mature luminal 
(ductal and alveolar) and basal cells of the adult mammary epithelium. Cells are characterized with expression of 
different surface markers—which allow for phenotypic identifying of the subpopulations. Normal mammary stem 
cells (MSC) must be distinguished from tumor stem cells (BCSCs). Deregulation of MaSC self-renewal may contribute 
to preneoplasia of mammary gland. In particular, deregulation of conserved signaling pathways, such as Wnt, Notch 
and hedgehog, is linked with oncogenesis. Breast tumors are divided into hypothetical subtypes according to different 
profiles and different origins of cells. We can find following subtypes: normal-like/claudin low, luminal and basal-
like and overexpressing HER2. Luminal progenitors cells (A and B) are mostly associated with good prognosis, those 
with HER2 overexpressing, also with luminal features, but usually associated with poor survival. Basal-like (the most 
heterogeneous) origin from luminal progenitors cells and those tumors are the most aggressive and with tendency to 
exhibit triple-negative phenotype. Additionally, those tumors are highly associated with BRCA1 gene mutations.
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3. MaSC and BCSC markers
The approaches to BCSC isolation at present include the following: surface marker sorting, 
aldehyde dehydrogenase activity assay, flow cytometry sorting side population, etc. [8]. 
CD44, CD24 and ALDH1 are the most commonly used biomarkers to identify the BCSC frac-
tion [31]. Two proteins, CD44 and CD24, were found in 2003 to be useful markers to distin-
guish tumor-initiating cells (TICs) from non-tumorigenic cells in BC [2].
CD44 (hyaluronan-binding transmembrane protein) is expressed in different isoforms and 
can have different glycosylation patterns [34]. Its smallest form (CD44s) is expressed in 
many cells, whereas its variant forms (CD44v) are particularly found in cancer cells. CD44v 
is involved in EMT, cellular migration, transendothelial migration and extravasation and it 
supports many cellular activities required to initiate tumor growth and metastasis [2, 34]. 
CD24 (heavily glycosylated membrane protein) downregulation may be required to prevent 
its interference with CD44-dependent invasiveness [35], though the underlying mechanism 
is not clear since CD24 also has tumor-promoting effects [2, 36]. The gene expression profile 
associated with CD44+/CD24− cells was demonstrated to correlate with a worse prognosis in 
BC [33] and approximately one-third of all circulating BC cells in the blood of BC patients is 
CD44+/CD24− [37]. CD44+/CD24− phenotype of cell surface markers has an increased ability 
to form tumors in immunosuppressed mice than the bulk of the tumor cells [38]. Maycotte 
et al. had analyzed CD24 and CD44 expression in MCF7 and MDA-MB-468 cell lines using 
assay based on flow cytometry. Analysed cells showed different levels of autophagic flux 
(“autophagic flux” is defined as the activity of autophagic degradation, which comprises 
autophagosomes formation, transportation of substartes and lysosomic degradation) [39]. 
CD24 expression was decreased in cells with low autophagic flux in both cancer cell lines. 
Similar results were obtained in cells expressing shRNA for ATG7 or BECN1, as these cells also 
showed low expression of CD24, whereas the expression of CD44 remained stable. Presented 
results indicate that cells with decreased autophagic activity have declined CD24 expression. 
These results suggest that autophagy can selectively regulate CSC maintenance in autophagy-
dependent breast cancer cells. It has been widely predicted that a quality control mechanism, 
like autophagy, is important for maintaining normal and cancer stem cell homeostasis [7, 38].
Palmer et al. [40] proposed a stem gene pluripotentiality signature as an indicator of the 
tumor grade in a variety of solid tumors, including BC. In addition to tissue samples, BCSC 
subpopulations have also been identified ex vivo within individual cultured BC cell lines. In 
triple-negative BC cell lines, CD44+/CD24−/low BCSCs were further classified into two subcat-
egories: the CD44high/CD24− mesenchymal-like basal B and the CD44high/CD24low epithelioid 
basal A, which displayed stronger tumor-initiating properties [15].
Recent data suggest that CD44 and CD24 may not be sufficient to distinguish the cancer cell 
subpopulation with CSC/TIC activity, so other proteins, like ALDH1 (aldehyde dehydro-
genase 1) and EpCAM (epithelial cell adhesion molecule), may also be required for cancer 
cells to develop tumor-initiating potential [2]. Members of ALDH1 family ALDH1A1 and 
ALDH1A3 are thought to be the most important for stem cell activity in cancer cells [41]. 
Recently, ALDH1 expression has been linked to the expression of RhoC [15, 42], a GTPase 
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known to be involved in metastasis. ALDH1-positive breast cancer cells could be identified 
by the ALDEFLUOR assay and they showed stem-like and tumor-initiating activities [15]. 
In the abovementioned experiment of Palmer et al. [40], distinct ALDEFLUOR-positive sub-
groups with stem cell characteristics have been shown to exist in eight BC cell lines and a 413 
gene-specific molecular signature characterizing these BCSCs was determined by microarray 
analysis.
EpCAM, a transmembrane protein, was considered to be a cellular adhesion molecule until 
it was discovered that it is able to activate c-myc involved in maintenance of stemness [36]. 
The level of EpCAM expression may be critical for defining stem cells. Recent reports dem-
onstrated that BCSC activity is associated with low EpCAM expression, whereas luminal or 
basal cells showed either high or no expression of EpCAM, respectively [43].
The aforementioned epithelial-like and mesenchymal-like BCSCs have been shown to inter-
convert from one type to another, presumably depending on the tumor phase and require-
ments [31]. The use of CD49f as an additional marker for the detection of BC cells lacking 
CK8/18/19 expression has been shown to possibly enhance the detection of circulating tumor 
cells (CTCs) involved in EMT-associated processes, such as drug resistance and metastasis 
[44]. CD44+/CD24− cells express epithelial-mesenchymal transition (EMT) genes [17], display 
a quiescent phenotype and are localized in the tumor periphery, possibly promoting tumor 
spreading. The characteristic pattern of surface markers expression (CD44+/CD24−/low) was 
found mostly in molecular subtype of breast tumors presenting low expression of claudin. It 
is accompanied by EMT-associated genes, like N-cadherin, FoxC2 and Zeb [17]. In contrast, 
ALDH1+ cells are situated within the tumor. They are typical epithelial cells, expressing mes-
enchymal-epithelial transition (MET) genes and high rate of proliferation, which can influ-
ence tumor progression. All these subpopulations are similarly expressing a large number 
of genes, which were confirmed by high-throughput gene expression profiling (microarray 
analyses). BCSCs are suggested to have hallmarks of both types of normal MaSCs, epithe-
lial (EpCAM+/CD49f+) and mesenchymal (EpCAM−/CD49f+). According to research results, 
BCSCs with phenotype ALDH1+/CD44+/CD24- are more aggressive and exhibit big meta-
static potential. In the immunosuppressed mice, it was possible to induce tumor growth using 
just a few ALDH1+/CD44+/CD24- cells [31].
In human breast tumor cells, phenotype CD44+/CD24low is connected with basal-like tumors, in 
particular with inherited BRCA1 BC. Additionally, the cells are expressing the CD49f marker 
and their status is CK5/14high EGFRhigh and ERlow, PRlow, HER-2low. It is worth noting that basal-like 
tumors are often linked to poorer prognosis. The occurrence of the CD44+/CD24low phenotype 
was found to be lower in tumors of luminal type and particularly HER-2+ tumors, irrespective 
of ER status [11]. Results of a different study demonstrated the presence of BCSC subtypes in a 
CTCs population, in peripheral blood samples taken from 30 patients. In total number of 1439 
CTCs, 35% of the CTCs in 2/3 patients displayed the CD44+/CD24−/low phenotype, while 17.7% 
CTCs selected in seven patients revealed phenotype ADLH1high/CD24−/low [45].
β1-integrin subunit (CD29) has also been implicated in the phenotypic characterization 
of BCSCs. It has been shown that BRCA1 mutant cancer cell lines contain CD24+CD29+ or 
CD24+CD49f+ cells, with increased proliferation and colony-forming ability [15].
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In BCTCs epithelial markers expression is routinely detected and therefore, many isolation 
techniques are based on the use of specific antibodies, like EpCAM and MUC1. For exam-
ple, for EpCAM identification, the most popular tests are CellsearchTM system (Veridex LLC, 
Raritan, NJ, USA) approved by the US Food and Drug Administration, the herringbone chip, 
the AdnaTest breast cancer detection kit, fluorescence-activated cell sorting (FACS) analysis 
and the microfluidic technology. Apart from the peripheral blood, BCSCs have also been iso-
lated directly from the primary or metastatic tumors of breast cancer patients [31].
Other techniques used for stem cell isolation are 3D cultivation in cell cultures spheroids. 
Stem cells are detectable by light microscopy as small and light cells (SLC) and have the 
ability to maintain DNA staining (using BrdU) due to their low proliferative activity [46]. 
However, it was shown that only 15% of [3H] thymidine-positive cells are also positive for one 
of the two stem cell markers p21CIP1 or Musahi-1 (MSi-1) [47].
The next marker worth mentioning is CD133 (prominin-1). Hematopoietic progenitors and 
adult stem cells normally express this transmembrane glycoprotein. It is a well-established 
melanoma and brain CSC marker. In addition, the expression of CD133 has been also detected 
in BCSCs and has been associated with resistance to chemotherapy in BC biopsies [48]. 
Furthermore, distinct CD44+/CD24− and CD133+ subpopulations with CSC characteristics have 
been detected in BRCA1 breast tumors, while CD44posCD49fhiCD133/2hi cells were character-
ized by xenograft-initiating capacity in estrogen receptor–negative BC [15]. Co-expression 
of stem (ALDH1) and EMT (TWIST) markers has been demonstrated in CTCs from patients 
with early and metastatic BC. The majority of CTCs expressing the SC marker CD133 also 
co-expressed the EMT marker N-cadherin and vice versa. The expression of CD133 in CTCs 
of BC patients has been suggested to promote chemoresistance [15]. Basal-type breast tumors 
with elevated SLUG expression were shown to overexpress stem-like genes, including CD133 
[20]. Additional studies revealed that BC overexpressing SLUG display increased proportions 
of CD44+/CD24− CSCs, suggesting that transcriptional programs induced by SLUG promote 
stemness [49].
Activation of some genes is proposed to be associated with stem cell phenotypic character-
istics, for example, Sox2 gene (a transcription factor involved in the maintenance of pluri-
potency of undifferentiated embryonic stem cells) [15]. Activation of this gene is typical for 
early steps of BC development and characterizes tumors with basal-like phenotype. Increased 
expression of Sox2 is analyzed as prognostic predictor of BC. Also, mutations in p53 are repre-
sentative for BC with stem cell-like patterns. It is suggested that loss of p53 function promotes 
dedifferentiation and is positively selected during tumor progression [15, 50].
4. The role of microenvironment in BC progression: stem cell niche
Stem cell niche refers to a microenvironment in which stem cells reside. The anatomical niche 
for SC is composed of different compartments [51]. Signals from surrounding cells (stromal 
cells, a specific type of fibroblast which interacts with the stem/progenitor cells via surface 
receptors, gap junctions, cytokines, growth factors, hormones, etc.) and extracellular matrix 
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(ECM) seem to be involved in regulation of SC activity, regulation of SC renewal and sur-
vival [1]. Since mammary gland is an endocrine-responsive organ, many hormonal factors 
are analyzed also in connection with stem cells, for example, the biological influence of E2 
and P on the compartment of stem and progenitor cells is largely unknown. However, it is 
assumed that the stem cells are estrogen receptor (ER) negative, whereas the progenitor cells 
are ER positive [2]. The role of BRCA1 gene in human ER− stem/progenitor cell differentiation 
into ER + luminal epithelial cells has been revealed in the latest scientific findings [11]. ER− 
stem cell transition into ER+ progenitor cells is precluded by BRCA1 deletion. Studies dem-
onstrated that women with heterozygous mutations in the BRCA1 gene are more susceptible 
to breast and ovarian cancers and the tumors formed were mostly of basal-like phenotype, 
showing characteristic deficiency of ER, PR and HER-2 receptors.
As mentioned above, deregulation of the microenvironmental homeostasis of normal SC is 
suggested to contribute to their neoplastic transformation [52]. The activation of the EMT 
program has been associated with the acquisition of SC traits by normal and neoplastic cells 
[15]. Transcription factors involved in EMT (e.g. Snail, Twist and Zeb) have also been found 
to induce SC properties in human mammary carcinoma cells [15]. Environmental cues from 
signaling molecules, which induce EMT in BC such as IL-6, can promote pluripotency in 
breast cancer cells via a positive feedback loop including NF-kB, Lin28 and Let-7 miRNA [15].
5. miRNA and stem cells in breast cancer
MicroRNAs are negative regulators of genes, repressing expression at the posttranscriptional 
level [53]. They also regulate various properties of CSC, including self-renewal, differentia-
tion, proliferation and fate determination, by affecting several key signaling pathways at the 
molecular level. Many different miRNA families have already been connected with suppress-
ing/promoting cancer cells. For example, miR-125a is known tumor suppressor in bulk tumor 
cells of BC origin [53, 54]; however, it has been shown that miR-125a plays a different role 
in breast epithelial SC, which is cancer promotion [53]. MicroRNA profiling of BCCSs indi-
cated that miR-200c, miR-203 and miR-375 expression was significantly inhibited, whereas 
the expression of miR-125b, miR-100, miR-221 and miR-222 was most notably enhanced 
[55]. Expression analysis of miRNAs in both normal mouse and human mammary tissue has 
revealed three conserved clusters of miRNAs, miR-200C-141, miR-200b-200a-429 and miR-
183-96-182, that appear to be downregulated in MaSC and putative BCSCs [56, 57]. In humans, 
miR-93 level was significantly higher in luminal progenitor cells than in the MaSC-enriched 
population and overexpression of this miRNA biased these cells toward a luminal fate [58].
MiR-200 family serves as a key mediator of CSC due to its prominent role as an EMT regulator. 
These family members are downregulated in BCCSs due to epigenetic alternation, in compar-
ison with non-tumorgenic cancer cells [59]. Downregulation of miR-200 expression expands 
the SC compartment and promotes BC progression. The tumor suppressor p53, which can 
activate miR-200c by direct binding to miR-200c promoter sites, is reported to regulate both 
EMT and CSCs [60]. Similar results were obtained in the case of miR-22, a strong inhibi-
tor of miR-200 promoter demethylation, which is connected with tumor invasiveness and 
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metastatic properties [59]—therefore, miR-22 is a crucial epigenetic modifier and promoter 
of EMT and cancer stemness toward metastasis [61]. In addition to miR-200 family, miR-21 
and MiR-302/369 have also been proposed to regulate EMT and CSC. In BC, the depletion of 
miR-21 expression leads to reversal of EMT and decreased CSC numbers through inactivation 
of AKT/ERK pathway [60]. MiR-302/369 cluster members can directly target EMT genes, like 
TGF-beta receptors or the RhoC and the downregulation of miR-302/369 promotes the switch 
of fibroblasts into somatic stem cells [60].
miRNAs can also regulate the breast cancer cell interactions with other cells by affecting cer-
tain genes, for example, Tac1 gene, linked to BC, regulates breast cancer cell interaction with 
the mesenchymal stem cells. Three miRNAs—miR-130a, miR-206 and miR-302a—have been 
shown to regulate Tac1 expression and their action against Tac1 may affect quiescence of 
breast cancer cells in the marrow cavity [11].
6. Signaling pathways regulating MaSC and contributing 
to the etiology of breast cancer
Wnt (wingless), Hh (hedgehog), Notch and BMP/TGF-β (bone morphogenetic proteins/trans-
forming growth factor β) signaling pathways contribute to the self-renewal of stem and/or 
progenitor cells in a variety of organs. When deregulated, these pathways can contribute to 
oncogenesis [59].
The Notch pathway has been shown to play a particular role in MaSC expansion [62, 63] and 
promotes BC progression by supporting EMT [11, 64]. Overexpression of the Notch pathway 
components has been linked to decreased survival of BC patients [65]. In a large propor-
tion of BCs, epigenetic mechanisms that activate Notch signaling were related to the role 
of miR-146a, which targets NUMB, a negative regulator of Notch [59]. Inhibition of Notch1 
with specific antibodies significantly reduced the CD44+CD24−/low subpopulation (BCSCs) and 
diminished the incidence of brain metastases from BCC.
β-Catenin, a downstream target of Wnt signaling pathway, has been identified as a crucial sur-
vival signal for MaSC and a balance modulator between differentiation and stemness in adult 
stem cell niche in the mammary gland [59]. Overexpression of Wnt in mouse mammary glands 
can also lead to increased mammary tumor formation. Such tumors contain cells of both basal/
myoepithelial and luminal phenotypes, suggesting an origin from a common precursor [11, 59].
In the hedgehog pathway, Patched (PTCH) transmembrane protein is a receptor for the 
hedgehog family of signaling molecules (Sonic-Shh, Indian-Ihh and Desert-Dhh) [59] and 
has been connected to early embryonic tumorigenesis [11]. PTCH constitutively represses Hh 
pathway activity through its interaction with a transmembrane protein Smoothened (SMO) 
[59]. Overexpression of these pathway components, that is, Shh, Ptch1 and Gli1, has been 
found in majority of human BCs.
Furthermore, studies demonstrated that EMT stimulation by TGF-β co-occurs with BCSC 
formation [66]. BCSCs with CD44+/CD24−/low phenotype show increased expression of many 
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genes which are known to be TGF-β targets and they are typical for mesenchymal and migra-
tory cell type. In one of the experiments, when MDA-MB-231 cells (model of BC) were injected 
to athymic mice, the change in TGF-β actions was observed. The cancer-promoting actions 
(tumorgenic and metastatic) of TGF-β were counteracted by BMP7 or BMP2/7 heterodimer 
[59], which diminished Smad signaling pathway activity and increased cancer cell invasive-
ness. Additionally, the activity of pro-survival and anti-apoptotic pathways is often increased 
in CSCs. Typically, for example, JAK/STAT pathway is highly activated [59].
7. Ways of targeting cancer stem cells: pharmacological agents
Although targeting BCSCs brings hope for future treatment of BC and is widely tested on the 
basic research level, a disproportionally limited number of clinical trials evaluating the effect 
of treatment on the expression of BCSC biomarkers are in progress [31].
Among the tested treatment approaches are those regulating the activity of signaling path-
ways. The targeting of BCSCs involves the disruption of BCSC survival signaling pathways 
(i.e., Notch, HER2, hedgehog, Wnt, PI3K/Akt/mTOR, interleukin 8, TGF-beta) [31]. Targeting 
Notch signaling has become a promising field in the treatment of stem cells in breast cancer. 
By inhibiting the Notch pathway, the CSC population can be reduced along with improved 
responses to chemotherapy [67]. Several inhibitors of Wnt signaling molecules are under 
investigation with reference to several cancers [68]. For example, inhibition of the Notch sig-
naling pathway by γ-secretase inhibitors (GSI) has been shown to reduce the pool of BCSCs 
[15, 62]. GSI and other drugs that interfere with the Notch pathway are currently under con-
sideration as new options to treat BC [65]. Because there is a link between the Notch and Her2-
dependent pathways [69], blocking either of them was found to affect CSC survival. Hence, 
Her2 inhibitors, such as trastuzumab, may be potential additional drugs suitable for targeting 
CSC [70]. Several scientific groups have exploited cyclopamine (SMO signaling inhibitor), to 
inhibit the Hh cascade, thereby inhibiting the growth, invasion and metastasis of breast, pros-
tatic, pancreatic and brain malignancies both in vitro and in vivo [71]. PKF118-310, an inhibitor 
of Wnt signaling pathway, was recently reported to eliminate BCSCs in a HER2 overexpress-
ing mouse model. Vismodegib, GDC-0449, a hedgehog inhibitor, can block tumor growth 
in tamoxifen-resistant BC xenografts [31]. Everolimus (RAD001), an inhibitor of PI3K/Akt/
mTOR pathway, halted tumor growth of SC in primary breast cancer cells and cell lines and 
was particularly effective when administered in combination with docetaxel [72].
The resistance of BCSCs to chemotherapeutic drugs leads to the reconstitution of the ini-
tial tumor cell population and disease progression [15]. Conventional therapies targeting the 
tumor bulk have proven insufficient for the eradication of CSC. For example, conventional 
therapies based on mitotic interference of taxanes (paclitaxel and docetaxel) [73] do not tar-
get the subpopulation of quiescent CSC in a tumor. Bhola et al. [74] reported that paclitaxel 
increased IL-8 expression by autocrine TGF-β signaling and enriched CSC. Interestingly, 
Gupta et al. reported that SAL, a polyether antibiotic widely used in veterinary medicine, is a 
potent agent able to selectively target BCSCs and to inhibit mammary tumor growth in vivo 
[43]. Since autophagy promotes the maintenance of BCSCs [75], SAL can inhibit autophagy 
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and lysosomal proteolytic activity in both BCSCs and cancer cells [76]. It also acts as an inhibi-
tor of potassium ionophore in Wnt signaling.
Another therapeutic approach is blocking the ABC transporters expressed in most CSC [13]. 
For instance, tyrosine kinase inhibitors (TKIs) act by binding to ATP and preventing it from 
binding to the ATP-binding site of several oncogenic tyrosine kinases. It has been reported 
that some TKIs, such as nilotinib (Tasigna), can efficiently reduce the activity of ABCB1 and 
ABCG2 transporters. Apatinib (YN968D1) was tested on breast cancer cell lines and in xeno-
graft models of breast cancers overexpressing ABCG2 and/or ABCB1. In combination with 
paclitaxel, it significantly increased the activity of paclitaxel in the animal models. The thera-
peutic use of ABC transporters inhibitors has failed so far because of the toxicity issues [13].
One of the most recent innovative approaches in breast cancer therapy is the recruitment of 
normal stem cells for the eradication of tumor cells. It has been pointed that mesenchymal 
stem cells (MSCs) have “tumor tropism,” which means that they show the ability of migra-
tion not only toward the sites of inflammation or injury, but also importantly to the tumor 
microenvironment.
Other tested options include the following: targeting of CSC metabolic pathways, the use of 
miRNAs, the use of small inhibitors as salinomycin, cancer immunotherapy, drugs involved 
in the treatment of noncancer diseases and nanotechnology (nanodrugs can easily accumulate 
within tumor sites due to their enhanced vascular permeability) [31].
8. Conclusions
Scientific findings from breast cancer studies have revealed that the SC content in breast 
tumor correlates with its invasiveness and the outcome of the disease. The resistance of 
BCSCs to chemotherapeutic drugs and other conventional BC therapies has led scientists to 
move toward establishment of novel therapeutic approaches. Current knowledge about BCSC 
characteristics and regulators still allows only for evaluation of those therapies on an experi-
mental level of preclinical studies. The most efficient cancer treatment protocols remain to be 
established on the basis of simultaneous targeting of BCSCs and bulk tumor cells. Therefore, 
there is still a great need for profound studies, which would extend our knowledge about 
stem cells and the interplay between these cells and tumor microenvironment. Looking at the 
practical aspects of BCSC usage one of the biggest challenges that still need to be resolved is 
the isolation of their population from the patients’ blood.
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IL-6 Interleukin 6
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mTOR Mammalian target of rapamycin kinase
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PI3K Phosphoinositide 3-kinase
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RhoC Small signaling G protein, Ras homolog gene family, member C
SC Stem cells
Shh Sonic signaling molecule (hedgehog family)
shRNA Small hairpin RNA
SLC Small and light cells
SLUG Snail2 and zink finger protein
SMA Smooth muscle actin
The Role of Stem Cells in Breast Cancer
http://dx.doi.org/10.5772/66904
243
SMO Smoothened transmembrane protein
Sox2 SRY—(sex determining region Y)—box2
Src Protooncogene non-receptor tyrosine-protein kinase Src
STAT Signal transducers and activators of transcription
TGF-beta Transforming growth factor beta
TIC Tumor-initiating cells
TKIs Tyrosine kinase inhibitors
TWIST Twist-related protein and transcription factor
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